Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype.

Particulate vaccines are emerging promising technologies for the creation of tunable prophylactics against a wide variety of conditions. Vesicular and solid biodegradable polymer platforms, exemplified by liposomes and polyesters, respectively, are two of the most ubiquitous platforms in vaccine delivery studies. Here we directly compared the efficacy of each in a long-term immunization study and in protection against a model bacterial antigen. Immunization with poly(lactide-co-glycolide) (PLGA) nanoparticles elicited prolonged antibody titers compared to liposomes and alum. The magnitude of the cellular immune response was also highest in mice vaccinated with PLGA, which also showed a higher frequency of effector-like memory T cell phenotype, leading to an effective clearance of intracellular bacteria. The difference in performance of these two common particulate platforms is shown not to be due to material differences but appears to be connected to the kinetics of antigen delivery. Thus, this study highlights the importance of sustained antigen release mediated by particulate platforms and its role in the long-term appearance of effector memory cellular response.

[1]  A. Altman,et al.  Immunomodifiers in vaccines. , 1989, Advances in veterinary science and comparative medicine.

[2]  E. Wherry,et al.  Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. , 2007, Immunity.

[3]  S. Broderick,et al.  Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants. , 2011, Biomaterials.

[4]  Marcos Garcia-Fuentes,et al.  Nanoparticles as protein and gene carriers to mucosal surfaces. , 2008, Nanomedicine.

[5]  S. Kaech,et al.  Generation of effector CD8+ T cells and their conversion to memory T cells , 2010, Immunological reviews.

[6]  C. Figdor,et al.  The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. , 2011, Biomaterials.

[7]  Naveen Palath,et al.  Synthetic nanoparticle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo. , 2011, Vaccine.

[8]  C. Kriegel,et al.  Nanotechnology solutions for mucosal immunization. , 2010, Advanced drug delivery reviews.

[9]  D. Keskin,et al.  Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. , 2011, Biomaterials.

[10]  Yung-Fu Chang,et al.  Leptospira immunoglobulin-like protein A variable region (LigAvar) incorporated in liposomes and PLGA microspheres produces a robust immune response correlating to protective immunity. , 2009, Vaccine.

[11]  P. Klenerman,et al.  A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Marrack,et al.  Towards an understanding of the adjuvant action of aluminium , 2009, Nature Reviews Immunology.

[13]  Nikhil S. Joshi,et al.  Effects of Signal 3 during CD8 T cell priming: Bystander production of IL-12 enhances effector T cell expansion but promotes terminal differentiation. , 2009, Vaccine.

[14]  C. Russell Middaugh,et al.  Nanotechnology in vaccine delivery☆ , 2008, Advanced Drug Delivery Reviews.

[15]  Yvonne Perrie,et al.  Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[16]  Bali Pulendran,et al.  Translating Innate Immunity into Immunological Memory: Implications for Vaccine Development , 2006, Cell.

[17]  T. Fahmy,et al.  Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. , 2011, Trends in biotechnology.

[18]  N. Valiante,et al.  Recent advances in the discovery and delivery of vaccine adjuvants , 2003, Nature Reviews Drug Discovery.

[19]  Yong‐Chan Chung,et al.  Enhanced adjuvantic property of polymerized liposome as compared to a phospholipid liposome. , 2002, Journal of biotechnology.

[20]  PEG-PBLG nanoparticle-mediated HSV-TK/GCV gene therapy for oral squamous cell carcinoma. , 2008, Nanomedicine.

[21]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[22]  S. Geary,et al.  Nanoparticle Delivery Systems in Cancer Vaccines , 2011, Pharmaceutical Research.

[23]  Y. Perrie,et al.  Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres , 2008, Journal of drug targeting.

[24]  E. Unanue,et al.  Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. , 1991, Journal of immunology.

[25]  Kendall A. Smith,et al.  Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. , 2010, Immunity.

[26]  E. Fikrig,et al.  TLR9-Targeted Biodegradable Nanoparticles as Immunization Vectors Protect against West Nile Encephalitis , 2010, The Journal of Immunology.

[27]  R. Ahmed,et al.  From vaccines to memory and back. , 2010, Immunity.

[28]  T. Fahmy,et al.  Application of nanotechnologies for improved immune response against infectious diseases in the developing world. , 2010, Advanced drug delivery reviews.

[29]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[30]  Bali Pulendran,et al.  Immunological mechanisms of vaccination , 2011, Nature Immunology.

[31]  A. Allison,et al.  Liposomes as immunological adjuvants. , 1976, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[32]  J. Harty,et al.  Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination , 2005, Nature Medicine.

[33]  B. Adair Nanoparticle vaccines against respiratory viruses , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[34]  Sang-Jun Ha,et al.  Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. , 2006, Journal of immunology.

[35]  Richard A Flavell,et al.  Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. , 2009, Vaccine.

[36]  D. Irvine,et al.  Antigen-Displaying Lipid-Enveloped PLGA Nanoparticles as Delivery Agents for a Plasmodium vivax Malaria Vaccine , 2012, PloS one.

[37]  R. Dudani,et al.  Multiple Mechanisms Compensate to Enhance Tumor-Protective CD8+ T Cell Response in the Long-Term Despite Poor CD8+ T Cell Priming Initially: Comparison Between an Acute Versus a Chronic Intracellular Bacterium Expressing a Model Antigen1 , 2002, The Journal of Immunology.

[38]  H. Merkle,et al.  PEGylation as a tool for the biomedical engineering of surface modified microparticles. , 2008, Journal of pharmaceutical sciences.

[39]  L. Bockenstedt,et al.  The impact of nanoparticle ligand density on dendritic-cell targeted vaccines. , 2011, Biomaterials.

[40]  G. Patel,et al.  Archaeosome Vaccine Adjuvants Induce Strong Humoral, Cell-Mediated, and Memory Responses: Comparison to Conventional Liposomes and Alum , 2000, Infection and Immunity.

[41]  D. Rahman,et al.  Biodegradable microparticles as controlled release antigen delivery systems. , 1991, Immunology.

[42]  Bhavna,et al.  Potential of nanoparticulate drug delivery systems by intranasal administration. , 2010, Current pharmaceutical design.

[43]  L. Lefrançois,et al.  Preferential Localization of Effector Memory Cells in Nonlymphoid Tissue , 2001, Science.

[44]  R. Langer,et al.  The pharmacokinetics of, and humoral responses to, antigen delivered by microencapsulated liposomes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Nikhil S. Joshi,et al.  Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. , 2007, Immunity.

[46]  Ronald N Germain,et al.  Vaccines and the future of human immunology. , 2010, Immunity.

[47]  Wah Chiu,et al.  Interbilayer-Crosslinked Multilamellar Vesicles as Synthetic Vaccines for Potent Humoral and Cellular Immune Responses , 2011, Nature materials.

[48]  D. Birx,et al.  Liposome‐stabilized oil‐in‐water emulsions as adjuvants: Increased emulsion stability promotes induction of cytotoxic T lymphocytes against an HIV envelope antigen , 2004, Immunology and cell biology.

[49]  I. Mellman,et al.  Design opportunities for actively targeted nanoparticle vaccines. , 2008, Nanomedicine.